These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33647260)

  • 1. Small nucleic acids and the path to the clinic for anti-CRISPR.
    Barkau CL; O'Reilly D; Eddington SB; Damha MJ; Gagnon KT
    Biochem Pharmacol; 2021 Jul; 189():114492. PubMed ID: 33647260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationally Designed Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas9.
    Barkau CL; O'Reilly D; Rohilla KJ; Damha MJ; Gagnon KT
    Nucleic Acid Ther; 2019 Jun; 29(3):136-147. PubMed ID: 30990769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of the CRISPR/Cas system in gene editing and nucleic acid detection of parasitic diseases: a review].
    Yan S; Yang S; Yang H; Xin Y; Xu B; Hu W; Lu Y; Zheng B
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2024 Jun; 36(3):314-320. PubMed ID: 38952320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in CRISPR-Cas systems for RNA targeting, tracking and editing.
    Wang F; Wang L; Zou X; Duan S; Li Z; Deng Z; Luo J; Lee SY; Chen S
    Biotechnol Adv; 2019; 37(5):708-729. PubMed ID: 30926472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering the Delivery System for CRISPR-Based Genome Editing.
    Glass Z; Lee M; Li Y; Xu Q
    Trends Biotechnol; 2018 Feb; 36(2):173-185. PubMed ID: 29305085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
    Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
    Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonviral Nanoparticles for CRISPR-Based Genome Editing: Is It Just a Simple Adaption of What Have Been Developed for Nucleic Acid Delivery?
    Qiu M; Glass Z; Xu Q
    Biomacromolecules; 2019 Sep; 20(9):3333-3339. PubMed ID: 31342740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR diagnostics: Underappreciated uses in perinatology.
    Pan A; Kraschel KL
    Semin Perinatol; 2018 Dec; 42(8):525-530. PubMed ID: 30415764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multiplexed CRISPR targeting platforms.
    Cao J; Xiao Q; Yan Q
    Drug Discov Today Technol; 2018 Aug; 28():53-61. PubMed ID: 30205881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas: A powerful tool for gene function study and crop improvement.
    Zhang D; Zhang Z; Unver T; Zhang B
    J Adv Res; 2021 Mar; 29():207-221. PubMed ID: 33842017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR-Cas-mediated diagnostics.
    Li L; Shen G; Wu M; Jiang J; Xia Q; Lin P
    Trends Biotechnol; 2022 Nov; 40(11):1326-1345. PubMed ID: 35595574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of CRISPR-Mediated Nucleic Acid Detection Technologies and Their Applications in the Livestock Industry.
    Zhang X
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The CRISPR-Cas system: beyond genome editing].
    Croteau FR; Rousseau GM; Moineau S
    Med Sci (Paris); 2018 Oct; 34(10):813-819. PubMed ID: 30451675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational designs of in vivo CRISPR-Cas delivery systems.
    Xu CF; Chen GJ; Luo YL; Zhang Y; Zhao G; Lu ZD; Czarna A; Gu Z; Wang J
    Adv Drug Deliv Rev; 2021 Jan; 168():3-29. PubMed ID: 31759123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications.
    Pyzocha NK; Chen S
    ACS Chem Biol; 2018 Feb; 13(2):347-356. PubMed ID: 29121460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-scale CRISPR pooled screens.
    Sanjana NE
    Anal Biochem; 2017 Sep; 532():95-99. PubMed ID: 27261176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing.
    Aquino-Jarquin G
    Mol Genet Metab; 2021; 134(1-2):77-86. PubMed ID: 34391646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditional Control of CRISPR/Cas9 Function.
    Zhou W; Deiters A
    Angew Chem Int Ed Engl; 2016 Apr; 55(18):5394-9. PubMed ID: 26996256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.